GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (NAS:ABIO) » Definitions » Degree of Operating Leverage

ABIO (ARCA biopharma) Degree of Operating Leverage : 0.00 (As of Jun. 2024)


View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. ARCA biopharma does not have enough data to calculate Degree of Operating Leverage.


ARCA biopharma Degree of Operating Leverage Historical Data

The historical data trend for ARCA biopharma's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Degree of Operating Leverage Chart

ARCA biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ARCA biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ARCA biopharma's Degree of Operating Leverage

For the Biotechnology subindustry, ARCA biopharma's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARCA biopharma's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Degree of Operating Leverage falls into.


;
;

ARCA biopharma Degree of Operating Leverage Calculation

ARCA biopharma's Degree of Operating Leverage for the quarter that ended in Jun. 2024 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -9.131 (Jun. 2024) / -7.869 (Jun. 2023) - 1 )/( 0 (Jun. 2024) / 0 (Jun. 2023) - 1 )
=0.1604/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


ARCA biopharma  (NAS:ABIO) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


ARCA biopharma Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


ARCA biopharma Business Description

Traded in Other Exchanges
N/A
Address
10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Executives
James P Flynn director 41 HARRIS CT, DANVILLE CA 94526
Funicular Funds, Lp 10 percent owner, other: See Footnote 1 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Funicular Fund, Lp other: See Footnote 1 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Jacob Ma-weaver other: See Remarks 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Christopher David Ozeroff officer: S.V.P., General Counsel 8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021
Robert E Conway director C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
C. Jeffrey Dekker officer: Chief Financial Officer 10170 CHURCH RANCH WAY, WESTMINSTER CO 80021
Thomas A Keuer officer: Chief Operating Officer C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021
Brian L. Selby officer: VP, Finance 11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020
Venrock Healthcare Capital Partners Lp 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Scott D Sandell 10 percent owner
David M Mott 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Forest Baskett 10 percent owner
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202